Compare DOO & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOO | APGE |
|---|---|---|
| Founded | 1937 | 2022 |
| Country | Canada | United States |
| Employees | 17000 | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | DOO | APGE |
|---|---|---|
| Price | $56.29 | $82.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $85.67 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 711.8K | 520.1K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.48 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $338.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.83 | $34.34 |
| 52 Week High | $81.89 | $95.32 |
| Indicator | DOO | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 49.11 |
| Support Level | $52.74 | $73.06 |
| Resistance Level | $81.04 | $84.56 |
| Average True Range (ATR) | 2.13 | 3.39 |
| MACD | 0.31 | -0.93 |
| Stochastic Oscillator | 46.20 | 22.86 |
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested; Manitou was sold in the third quarter of fiscal 2026, and Telwater remains up for sale. At the end of fiscal 2026, the company sold its products through a network of more than 2,050 independent dealers and 140 distributors in around 110 countries.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.